IDH1 and glioblastoma: The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation represents a well-established molecular biomarker for prognosis and a predictive marker of response to alkylating therapy in IDH-wildtype glioblastoma.